Get started
CO DIAGNOSTICS INC COM USD0.001CO DIAGNOSTICS INC COM USD0.001CO DIAGNOSTICS INC COM USD0.001

CO DIAGNOSTICS INC COM USD0.001

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

0A50 trade ideas

CODX CHANGED EARNINGS UNTIL AFTER THE BELL ON THURSDAY PLS READCODX IS ONE OF THE STOCKS THAT IS UP TODAY, HOWEVER PLEASE READ BELOW: Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will release its first quarter 2020 earnings on May 14, 2020 after the close of trading on that day, and will hold an earnings call at 4:30 pm EDT. The call is expected to consist of prepared remarks by Company CEO Dwight Egan, and include mid-quarter guidance for the second quarter 2020. Analysts providing coverage for Co-Diagnostics will also be invited participate in a question and answer session.
NASDAQ:CODX
by mthompson45
$CODX Long Onto earnings 14th mayExpectations high among investors for the COVID testing company. Speculative but could be rewarding Indicators and volume improving Co-Diagnostics, Inc. is a molecular diagnostics company, which engages in the development, manufacture, and marketing of diagnostics technology. The company's products are utilized for tests that are designed using the detection and analysis of nucleic acid molecules. It also uses its proprietary technology to design tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.
NASDAQ:CODXLong
by RedHotStocks
CODX LONGAlthough CODX has Earnings Tomorrow I am Writing Long Term CODX has been involved with COVID testing from the jump start. If you want to place a long trade after tomorrow's announcement that would be ok also. I already have my long calls. The Mexican Department of Epidemiology has approved for sale a COVID-19 diagnostic test manufactured by Co-Diagnostics (NASDAQ: CODX). In addition, CoSara, a joint venture that the molecular diagnostics company formed in India, has also been cleared to sell test kits in the world's second-most populous country. The Centers for Medicare and Medicaid Services (CMS), which regulates all U.S. laboratory testing performed on humans, has also approved the sale of the test to roughly 260,000 clinical laboratories across the country.
NASDAQ:CODXLong
by mthompson45
$CODX $20 next target , Great run so farPrevious targets have been hit and stock remains in strong trajectory, Lets see if previous resistance will get tested and hold before earnings. Short interest high @21% Company profile Co-Diagnostics, Inc. is a molecular diagnostics company, which engages in the development, manufacture, and marketing of diagnostics technology. The company's products are utilized for tests that are designed using the detection and analysis of nucleic acid molecules. It also uses its proprietary technology to design tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.
NASDAQ:CODX
by Bullishcharts
1
$CODX Co-Doagnostics up on COVID testing DATA Uptrend support has held. Cluster of moving averages now resistance News release Co-Diagnostics (NASDAQ:CODX) perks up 10% premarket on light volume on the heels of performance data on its LogixSmart real-time PCR test that detects RNA from the SARS-CoV-2 virus in lower respiratory tract fluids. Tests performed in Australia (n=207), India (n=45) and Mexico (n not provided) showed 100% sensitivity and 100% specificity with no cross-reactivity with other viruses. It also says that the test detected more low-level positives than the CDC test while testing at the Minnesota Department of Health showed 100% concordance with another (unnamed) assay. Source Seekingalpha
NASDAQ:CODX
by Bullishcharts
$CODX can rise in the next daysContextual immersion trading strategy idea. Co-Diagnostics is a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests. Due to the spread of COVID-19, the demand for the company`s services rose. The demand for shares of the company looks higher than the supply. These and other conditions can cause a rise in the share price in the next days. So I opened a long position from $13,31; stop-loss — $12,62. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:CODXLong
by KozakHlib
2
$CODX long swing ideaI have an alert set just below $10 as I like this low float former runner long over $10 for a potential break out day tmrw. If it triggers an entry; my stop loss will be the LOD and my targets will be $10.50 and $11.00. Please note that it's very unlikely I'll hold this stock overnight except if it ends up having a massive breakout day pushing well past my $11 target. In this case, I'll overnight hold only 1/4 of my initial position which is unlikely to be greater than 25-50 shares.
NASDAQ:CODXLong
by elingford
1